<DOC>
	<DOCNO>NCT00684502</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability AZD2066 use multiple escalate dose panel . There separate panel young healthy volunteer elderly healthy volunteer . Each panel contain 10 volunteer randomly receive AZD2066 placebo . One panel run time fix dose give . After completion panel , Safety Review Committee decide study proceed next dose panel .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetics AZD2066 Young Elderly Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provision sign informed consent Clinically normal physical finding laboratory value judge investigator normal rest ECG . History somatic disease/condition , may interfere objective study , judge investigator . History previous ongoing psychiatric disease/condition include psychosis , affective disorder , anxiety disorder , borderline state personality disorder . Intake medicine ( except occasional paracetamol nasal spray ) within first 2 week first administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>AZD2066</keyword>
	<keyword>Pain condition</keyword>
</DOC>